[
  {
    "ts": null,
    "headline": "Eli Lilly: Still Expensive As Earnings Near, But Not Worthy Of A Downgrade",
    "summary": "Financial writer cautious on Eli Lilly stock despite strong performance, citing high valuation and underperforming drugs.",
    "url": "https://finnhub.io/api/news?id=ca252f8d2f0175b19346cf4e77df62c7d3f891418ce1cd2aea88d914a31354d2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736579106,
      "headline": "Eli Lilly: Still Expensive As Earnings Near, But Not Worthy Of A Downgrade",
      "id": 132377273,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2188209231/image_2188209231.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Financial writer cautious on Eli Lilly stock despite strong performance, citing high valuation and underperforming drugs.",
      "url": "https://finnhub.io/api/news?id=ca252f8d2f0175b19346cf4e77df62c7d3f891418ce1cd2aea88d914a31354d2"
    }
  },
  {
    "ts": null,
    "headline": "XLG: Outperforms The S&P500 Index",
    "summary": "Read here for an analysis of Invesco S&P 500 Top 50 ETF (XLG) for long-term capital growth, which outperforms the S&P 500 Index with top US stocks.",
    "url": "https://finnhub.io/api/news?id=41372635c7e80d675555d69b4c18d6e06128a8ef296afc39ea1298fb9ff7632a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736573382,
      "headline": "XLG: Outperforms The S&P500 Index",
      "id": 132376966,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1204684903/image_1204684903.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Read here for an analysis of Invesco S&P 500 Top 50 ETF (XLG) for long-term capital growth, which outperforms the S&P 500 Index with top US stocks.",
      "url": "https://finnhub.io/api/news?id=41372635c7e80d675555d69b4c18d6e06128a8ef296afc39ea1298fb9ff7632a"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: Still Much Room To Ride The Weight-Loss Wave",
    "summary": "Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a fair price target of $1,200. See more.",
    "url": "https://finnhub.io/api/news?id=c3f7280c3fbcdd9c9311cd40c8243dab4ff8ce623f2cde3ce54de3edcb55a822",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736570807,
      "headline": "Eli Lilly: Still Much Room To Ride The Weight-Loss Wave",
      "id": 132376826,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/147205781/image_147205781.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a fair price target of $1,200. See more.",
      "url": "https://finnhub.io/api/news?id=c3f7280c3fbcdd9c9311cd40c8243dab4ff8ce623f2cde3ce54de3edcb55a822"
    }
  }
]